570 related articles for article (PubMed ID: 21990576)
21. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
22. Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model.
Debie P; Vanhoeij M; Poortmans N; Puttemans J; Gillis K; Devoogdt N; Lahoutte T; Hernot S
Mol Imaging Biol; 2018 Jun; 20(3):361-367. PubMed ID: 29090412
[TBL] [Abstract][Full Text] [Related]
23. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
Huhtala T; Laakkonen P; Sallinen H; Ylä-Herttuala S; Närvänen A
Nucl Med Biol; 2010 Nov; 37(8):957-64. PubMed ID: 21055627
[TBL] [Abstract][Full Text] [Related]
24. Quantum dots-bevacizumab complexes for in vivo imaging of tumors.
Gazouli M; Bouziotis P; Lyberopoulou A; Ikonomopoulos J; Papalois A; Anagnou NP; Efstathopoulos EP
In Vivo; 2014; 28(6):1091-5. PubMed ID: 25398804
[TBL] [Abstract][Full Text] [Related]
25. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies.
Barrett T; Koyama Y; Hama Y; Ravizzini G; Shin IS; Jang BS; Paik CH; Urano Y; Choyke PL; Kobayashi H
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6639-48. PubMed ID: 17982120
[TBL] [Abstract][Full Text] [Related]
26. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
28. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
30. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.
Lee HJ; Ehlerding EB; Jiang D; Barnhart TE; Cao T; Wei W; Ferreira CA; Huang P; Engle JW; Cai W
Am J Cancer Res; 2019; 9(7):1454-1468. PubMed ID: 31392081
[TBL] [Abstract][Full Text] [Related]
31. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.
Yang Y; Zhang Y; Hong H; Liu G; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2066-76. PubMed ID: 21814852
[TBL] [Abstract][Full Text] [Related]
32. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model.
Hekman MCH; Rijpkema M; Bos DL; Oosterwijk E; Goldenberg DM; Mulders PFA; Boerman OC
J Nucl Med; 2017 May; 58(5):706-710. PubMed ID: 28126888
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
Saccomano M; Dullin C; Alves F; Napp J
Int J Cancer; 2016 Nov; 139(10):2277-89. PubMed ID: 27428782
[TBL] [Abstract][Full Text] [Related]
35. Serial in vivo imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy.
Ma T; Liu H; Sun X; Gao L; Shi J; Zhao H; Jia B; Wang F; Liu Z
Mol Pharm; 2015 Jan; 12(1):10-7. PubMed ID: 25397907
[TBL] [Abstract][Full Text] [Related]
36. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
[TBL] [Abstract][Full Text] [Related]
37. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
